DNA CHARACTERIZATION SERVICES FOR CCG, CRS/EOMI, CPTAC AND DCEG TASK ORDERTO PERIOD OF PERFORMANCE: 08/31/2019 - 08/30/2021 OPTION 1 PERIOD OF PERFO

CCG、CRS/EOMI、CPTAC 和 DCEG 的 DNA 表征服务 任务顺序执行周期：2019 年 8 月 31 日 - 2021 年 8 月 30 日 选项 1 执行周期

• 批准号: 10282703
• 负责人: STACEY GABRIEL
• 金额: $ 80.91万
• 依托单位: BROAD INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-31 至 2021-08-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10282703
• 关键词: Biocompatible Materials; Biological Assay; Cancer Center; DNA; DNA Sequence Alteration; DNA sequencing; Data; Division of Cancer Epidemiology and Genetics; Ensure; Genome; Genomics; Goals; Informatics; Institutes; Malignant Neoplasms; Methods; Methylation; Molecular; Performance; Play; Procedures; Quality Control; Research; Resources; Sampling; Services; Specimen; advanced analytics; analytical tool; base; cancer genomics; data integration; exome; experience; genome sequencing; improved; operation; programs; quality assurance; whole genome

The Broad Institute will establish a Genome Characterization Center (GCC) to support the Center for Cancer Genomics Pipeline, we propose to build on our 30 year track record as a Genome Center and apply a suite of well-validated platforms and advanced analytic tools to comprehensively characterize genomic alterations of cancer specimens. We will characterize at least 1,200 cancer cases per year as identified by the NCI Center for Cancer Genomics. We will apply DNA-based assays including low coverage whole genome sequencing (WGS), high coverage WGS, whole exome (WEX), targeted panel and methylation-based assays to identify a wide array of types of somatic alterations. We are able to accept and successfully analyze materials from FFPE specimens and have documented extensive experience with this type of sample.

布罗德研究所将建立一个基因组表征中心（GCC）来支持癌症基因组学中心的管道，我们建议在我们作为基因组中心 30 年的跟踪记录的基础上，应用一套经过充分验证的平台和先进的分析工具来全面地表征癌症样本的基因组改变。我们每年将描述 NCI 癌症基因组学中心确定的至少 1,200 个癌症病例的特征。我们将应用基于 DNA 的检测，包括低覆盖率全基因组测序 (WGS)、高覆盖率 WGS、全外显子组 (WEX)、靶向组和基于甲基化的检测来识别各种类型的体细胞改变。我们能够接受并成功分析 FFPE 样本中的材料，并记录了处理此类样本的丰富经验。